Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition

Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, Rene Gonzalez, Jose Lutzky, Steven J. O'Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil Ramaiya, Anita Giobbie-Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, F. Stephen Hodi

Research output: Contribution to journalArticlepeer-review

87 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition'. Together they form a unique fingerprint.

Medicine & Life Sciences